Trial Profile
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LIMMITLESS
- Sponsors AbbVie; AbbVie Germany
- 08 Mar 2024 This trial has been completed in Portugal, According to European Clinical Trials Database record.
- 06 Mar 2024 According to AbbVie media release, data from the study will be presented at American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego, California.
- 27 Jan 2024 This trial has been completed in France according to European Clinical Trials Database record